Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Wiest

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Science Immunology|March 10, 2023
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancerYini Zhu, Yun Zhao, Jiling Wen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Chemical Reviews|June 17, 2026
Organic Chemistry as a Catalyst for AI Innovation: Challenges, Methods, and Emerging ParadigmsNitesh V Chawla, Gisela A González-Montiel, Kehan Guo, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 4, 2019
2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 diseaseJessica Davidson, Elizabeth Molitor, Samantha Moores, et al.
Science Translational Medicine|May 22, 2015
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogsJonathan D Herman, Lauren R Pepper, Joseph F Cortese, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Cancer Discovery|November 13, 2021
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified NeuroblastomaAdam D Durbin, Tingjian Wang, Virangika K Wimalasena, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Science Immunology|March 10, 2023
Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancerYini Zhu, Yun Zhao, Jiling Wen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Chemical Reviews|June 17, 2026
Organic Chemistry as a Catalyst for AI Innovation: Challenges, Methods, and Emerging ParadigmsNitesh V Chawla, Gisela A González-Montiel, Kehan Guo, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 4, 2019
2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 diseaseJessica Davidson, Elizabeth Molitor, Samantha Moores, et al.
Science Translational Medicine|May 22, 2015
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogsJonathan D Herman, Lauren R Pepper, Joseph F Cortese, et al.
Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.
Cancer Discovery|November 13, 2021
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified NeuroblastomaAdam D Durbin, Tingjian Wang, Virangika K Wimalasena, et al.
Pageof 15